Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

References

• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. doi:10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012;13:239–246. doi:10.1016/S1470-2045(11)70393-X
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334. doi:10.1200/JCO.2012.44.2806
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–222. doi:10.1016/S1470-2045(13)70604-1
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–792. doi:10.1056/NEJMoa044238
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043. doi:10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. doi:10.1126/scitranslmed.3002003
   PubMed Web of Science ®Google Scholar
• Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30:433–440. doi:10.1200/JCO.2011.38.3224
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009;20:298–304. doi:10.1093/annonc/mdn635
   PubMed Web of Science ®Google Scholar
• Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69:3256–3261. doi:10.1158/0008-5472.CAN-08-4055
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Fujita Y, et al. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol. 2010;5:399–400. doi:10.1097/JTO.0b013e3181cee47e
   PubMed Web of Science ®Google Scholar
• Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521–528. doi:10.1038/nm.2713
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140–144. doi:10.1093/nar/gkj112
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269. doi:10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866. doi:10.1038/nrc1997
   PubMed Web of Science ®Google Scholar
• Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3ʹ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68:8535–8540. doi:10.1158/0008-5472.CAN-08-2129
   PubMed Web of Science ®Google Scholar
• Teo MT, Landi D, Taylor CF, et al. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis. 2012;33:581–586. doi:10.1093/carcin/bgr300
   PubMed Web of Science ®Google Scholar
• Xu J, Yin Z, Gao W, et al. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One. 2013;8:e77024. doi:10.1371/journal.pone.0077024
   Web of Science ®Google Scholar
• Hong MJ, Lee SY, Choi JE, et al. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. Oncotarget. 2016;7:15948–15958. doi:10.18632/oncotarget.7433
   Google Scholar
• Helwak A, Kudla G, Dudnakova T, et al. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell. 2013;153:654–665. doi:10.1016/j.cell.2013.03.043
   PubMed Web of Science ®Google Scholar
• Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–360. doi:10.1200/JCO.2009.24.7049
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Ziebarth JD, Cui Y. PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res. 2014;42:D86–91. doi:10.1093/nar/gkt1028
   PubMed Web of Science ®Google Scholar
• Higgins ME, Claremont M, Major JE, et al. CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res. 2007;35:D721–726. doi:10.1093/nar/gkl811
   Web of Science ®Google Scholar
• Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013;24:2080–2087. doi:10.1093/annonc/mdt127
   PubMed Web of Science ®Google Scholar
• Simon DN, Rout MP. Cancer and the nuclear pore complex. Adv Exp Med Biol. 2014;773:285–307.
   PubMed Web of Science ®Google Scholar
• Borden KLB. The Nuclear Pore Complex and mRNA Export in Cancer. Cancers. 2020;13:521.
   Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. cell. 2004;116:281–297. doi:10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Hazawa M, Lin DC, Kobayashi A, et al. ROCK-dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation. EMBO Rep. 2018;19:73–88. doi:10.15252/embr.201744523
   PubMed Web of Science ®Google Scholar
• Karacosta LG, Kuroski LA, Hofmann WA, et al. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells. Prostate. 2016;76:294–306. doi:10.1002/pros.23121
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Kalir T, Rahaman J, et al. Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. Am J Pathol. 2012;180:375–389. doi:10.1016/j.ajpath.2011.09.024
   PubMed Web of Science ®Google Scholar
• Lo H-W, Ali-Seyed M, Wu Y, et al. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1. J Cell Biochem. 2006;98:1570–1583. doi:10.1002/jcb.20876
   PubMed Web of Science ®Google Scholar
• Wang Y-N, Yamaguchi H, Huo L, et al. The translocon Sec61β localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem. 2010;285:38720–38729. doi:10.1074/jbc.M110.158659
   Web of Science ®Google Scholar
• Brand TM, Iida M, Luthar N, et al. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013;108:370–377. doi:10.1016/j.radonc.2013.06.010
   PubMed Web of Science ®Google Scholar
• Lin J-H, Lin D, Xu L, et al. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Oncotarget. 2017;8:3412. doi:10.18632/oncotarget.13787
   Google Scholar
• Taniguchi K, Okami J, Kodama K, et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008;99:929–935. doi:10.1111/j.1349-7006.2008.00782.x
   PubMed Web of Science ®Google Scholar
• Chang IS, Jiang SS, Yang JC, et al. Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors. Am J Respir Crit Care Med. 2017;195:663–673. doi:10.1164/rccm.201602-0300OC
   Web of Science ®Google Scholar
• Zhang L, Li QX, Wu HL, et al. SNPs in the transforming growth factor-beta pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib. Ann Oncol. 2014;25:1584–1590. doi:10.1093/annonc/mdu172
   Web of Science ®Google Scholar
• Jung M, Cho BC, Lee CH, et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012;53:1128–1135. doi:10.3349/ymj.2012.53.6.1128
   Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–640. doi:10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar